Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20122 in advanced solid tumors
NCT06927570Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-20122 in solid tumor (advanced stage), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose or Maximum Applicable Dose at 21 days. Started Apr 2025; status: recruiting.
02
Drugs
HS-20122
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06927570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927570.